Next Article in Journal
Circulating Tumor Cells for the Management of Renal Cell Carcinoma
Next Article in Special Issue
Liquid Biopsy Potential Biomarkers in Prostate Cancer
Previous Article in Journal
Effects of the Plastic of the Realistic GeePS-L2S-Breast Phantom
Previous Article in Special Issue
RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(3), 62;

Genome-Based Classification and Therapy of Prostate Cancer

Division of Cancer Genome Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, Heidelberg D-69120, Germany
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 30 July 2018 / Revised: 28 August 2018 / Accepted: 29 August 2018 / Published: 2 September 2018
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer)
Full-Text   |   PDF [1054 KB, uploaded 2 September 2018]   |  


In the past decade, multi-national and multi-center efforts were launched to sequence prostate cancer genomes, transcriptomes, and epigenomes with the aim of discovering the molecular underpinnings of tumorigenesis, cancer progression, and therapy resistance. Multiple biological markers and pathways have been discovered to be tumor drivers, and a molecular classification of prostate cancer is emerging. Here, we highlight crucial findings of these genome-sequencing projects in localized and advanced disease. We recapitulate the utility and limitations of current clinical practices to diagnosis, prognosis, and therapy, and we provide examples of insights generated by the molecular profiling of tumors. Novel treatment concepts based on these molecular alterations are currently being addressed in clinical trials and will lead to an enhanced implementation of precision medicine strategies. View Full-Text
Keywords: prostate cancer; genomics; copy number alterations; mutations; molecular markers; precision medicine; patient stratification prostate cancer; genomics; copy number alterations; mutations; molecular markers; precision medicine; patient stratification

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Angeles, A.K.; Bauer, S.; Ratz, L.; Klauck, S.M.; Sültmann, H. Genome-Based Classification and Therapy of Prostate Cancer. Diagnostics 2018, 8, 62.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top